General Home Investors News

Additional US$ 4 million received for next development steps of MedinCell’s 6-month active injectable bioresorbable subcutaneous contraceptive

By MedincellNovember 30, 2022March 15th, 2024No Comments

Additional US$ 4 million received for next development steps of MedinCell’s 6-month active injectable bioresorbable subcutaneous contraceptive

November 30, 2022

Previous PostMedinCell publishes its financial results for the first semester of 2022-2023
Next PostDetails of the financing agreement signed by MedinCell and the European Investment Bank (EIB)

Better medicine for all

Website by ScreenUp